This focused issue on “Right Ventricular Dysfunction” is edited by Drs. Martin Koestenberger, Harm Jan Bogaard, and Georg Hansmann.
Division of Pediatric Cardiology, Department of Pediatrics, Medical University Graz, Graz, Austria
Martin Koestenberger is a Professor of Pediatrics at the University of Graz, Austria. In August 2012, he became the Subhead of the Department of Pediatric Cardiology and focused in treatment of children with pulmonary hypertension. His clinical work in the Pediatric Cardiology Center led to the establishment of several normative echocardiographic values of the RV. His research group actually investigates the value of several echocardiographic RV parameters in children with pulmonary hypertension and RV dysfunction. He is involved in development of international recommendations for diagnostic care of children with PH as the Co-Chair of the European Pediatric Pulmonary Disease Network (https://www.pvdnetwork.org/). He is currently (starting October 2019) the Chair of the Working Group “Pulmonary Hypertension, Heart Failure and Transplantation” of the AEPC (https://www.aepc.org/pulmonary-hypertension-heart-failure-and-transplantation).
Harm Jan Bogaard, MD
Department of Pulmonary Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands
Harm Jan Bogaard is a Professor of Experimental Pulmonary Medicine and pulmonologist at Amsterdam UMC Center of Excellence for pulmonary hypertension. While most of his medical training took place in Amsterdam, he worked as a post-doctoral research fellow with physiologist Peter Wagner at the University of California San Diego and with pulmonary hypertension expert Norbert Voelkel at the University of Colorado, Denver. Bogaard was assistant professor of Medicine at Virginia Commonwealth University, Richmond. In his work, which was published in over 190 articles in peer-reviewed journals, Dr. Bogaard uses in vitro techniques and animal models to better understand mechanisms of pulmonary vascular disease and right heart failure, thereby searching for new treatment modalities. His clinical research focuses on the use of imaging methods, functional studies and liquid biopsy analysis to identify subgroups of pulmonary hypertension patients and predict treatment responses. Dr. Bogaard is Associate Editor of Thorax and Plos One and is European ambassador at the 3CPR Council of the American Heart Association. He chairs the Right Ventricle Group of Assembly 13 of the European Respiratory Society.
Georg Hansmann, MD, PhD, FESC, FAHA
Department of Pediatric Cardiology and Critical Care, Hannover Medical School, Hannover, Germany
Georg Hansmann is an Attending Pediatric/Congenital Cardiologist, Physician Scientist, and Professor at Hannover Medical School. His clinical focus is on heart and lung failure, pediatric and adult congenital heart disease, cardiac catheterization and cardiovascular imaging. Georg is the Director of the Pediatric Pulmonary Hypertension Program and the Pulmonary Vascular Research Center (PVRC). He works in the catheterization and echocardiography laboratories, and in the ACHD and Transplantation Centers, and attends on the intensive and intermediate care units.
Georg is the founding chair of the AEPC working group “Pulmonary Hypertension, Heart Failure and Transplantation” (2015-2018, then councilor/interim chair), founding chair of the European Pediatric PVD Network (EPPVDN; www.pvdnetwork.org
Focused issue outline:
- Introduction to this focused issue
- Molecular mechanisms of right ventricular dysfunction and heart failure in PAH
- Animal models of right ventricular dysfunction and failure
- Mechanics of right ventricular dysfunction in PAH and HFpEF
- Update on non-invasive imaging of right ventricular dysfunction
- How to detect and tackle right ventricular dysfunction in congenital heart disease
- Right ventricular dysfunction and long-term risk of sudden cardiac death
- Circulating non-coding RNAs and NT-proBNP to detect and categorize heart failure subtypes
- Treatment of right ventricular dysfunction and heart failure in PAH patients
- Molecular mechanisms of heart failure with preserved ejection fraction (HFpEF), with or without right ventricular dysfunction
- Treatment of Severe LV Diastolic Dysfunction in Postcapillary PH (HFpEF, hypoplastic left heart structures) with or without RV Dysfunction
- Cardiac Multiscale X-Ray Phase Contrast Tomography for Multiresolution Structural Investigation of the Right and Left Ventricle ex-vivo
- RV Function and Hemodynamic Effects of Macitentan in Pediatric PAH
- Emerging Therapies for RV Dysfunction and Failure
- Perioperative RV Dysfunction – The Anesthesiologist’s View